Sofpromed, a full service contract research organization (CRO) focused on cancer trial management, has announced the extension of its clinical operations to provide local service in additional countries in Europe, namely Portugal, France, Italy, Germany, and Bulgaria.
From its headquarters located in Palma de Mallorca, Spain, the company already manages multicenter oncology studies in various European member states, but now, as part of its international expansion strategy, its project management and monitoring teams will be strengthened to consolidate operations in the Portuguese, French, Italian, German, and Bulgarian markets.
According to Patricio Ledesma, Sofpromed’s Head of Clinical Operations: “Sofpromed is experiencing an exciting growth as full service CRO, with new multinational trials starting in 2019.
We want to ensure the best level of service for our clients, especially for US and European sponsors conducting large multicenter studies in Europe”.
Regarding the operational improvements foreseen in this new stage, Patricio Ledesma states: “The goal is to reinforce our service capabilities for international trials, focusing on the optimization of our project management and monitoring departments, led from our headquarters in Palma, which are located in a very strategic part of Europe. To this end, we will be adding new staff to our central offices”.
Sofpromed is an oncology-focused CRO providing trial management services to US and European sponsors, particularly in solid tumors (soft-tissue sarcomas, bone tumors, gastrointestinal, endometrial, ovarian, and breast cancer), hematologic malignancies (leukemia and lymphomas), and rare cancers.
